LingJunXing xiangxue pharmacy attaches great importance to the research and development innovation to build the modern Chinese medicine enterprise

News center - China website: news.china.com.cn

Time: 2013-06-17

        LingJunXing enterprise integrated innovation to build the modern traditional Chinese medicine

        Eye alone: buying companies in net profit increase 16 times

        Since 2011, the company's advantage of capital, has acquired HuaZhou guangdong traditional Chinese medicine factory, guangdong qingping pharmaceutical factory (after capital increase of guangdong xiangxue pharmaceutical co., LTD.), set up sichuan xiangxue pharmacy co., LTD., improve the production capacity, rich product variety and preparation type; Successively in shangri-la in yunnan, ningxia lund LiuPanShan investment built planting base of Chinese medicinal materials, improve the control ability of Chinese herbal medicine resources.

        Xiangxue pharmacy has finished Chinese medicine yinpian standardization technical transformation project, modern traditional Chinese medicine in hunan spring nine remit, acquisition of bozhou qiaocheng Shanghai Chinese medicine yinpian manufacturing industry pharmaceutical companies 70% of equity, enhance the Chinese herbal medicine, Chinese medicine yinpian comprehensive processing and manufacturing capacity, and Chinese medicine yinpian products category. WuJun xiangxue pharmacy, deputy general manager said with confidence, "the company's future is expected to become a leader in the Chinese medicine yinpian industry."

        Xiangxue pharmacy is understood to have Chinese traditional medicine superfine slices "of technical reserves," amd yinpian "is different from traditional Chinese medicine yinpian, amd technology to Chinese herbal medicine pieces into the ultrafine powder with a diameter of 75 microns below, make the cell walls of traditional Chinese medicine is broken, and the active components of Chinese herbal medicine can more easy to release, thus reducing the usage of traditional Chinese medicinal materials, convenient for patients to use.

        In addition, xiangxue pharmacy has been set up in chongqing xiangxue pharmacy co., LTD., the acquisition of shanxi new billion group of pharmaceutical industry. New drug circulation channels and circulation of the original sales channel integration, will strengthen the company's products marketing and expanding the scope of the marketing, deepen and expand its market share in the market.

        Xiangxue pharmacy acquisition, capital and nine biological, when applying for direct selling license, complete Chinese medicine health care products business sales strategy layout; Acquisition, capital and zhongshan yoplait, drug reference substance, standard production and operation conditions. Along with the advancement of important product strategy integration, company epitaxial growth got fully reflect.

        In xiangxue pharmacy buy these pharmaceutical companies, most notably a wholly-owned acquisitions HuaZhou guangdong traditional Chinese medicine factory. The factory mainly produce orange phlegm cough fluid, in 2011 by the xiangxue pharmacy after the acquisition, sales of the plant in 2012 from 107 million yuan to 145 million yuan, net income rose by 653300 yuan to 11.196 million yuan, net income all turned over 16 times.

        "Original HuaZhou traditional Chinese medicine factory scale is not big, the production and the management pattern, after we bought the company, the enterprise sales channels integrating into the snow, with more specifications of raw materials procurement and production management, effectively reduce the comprehensive cost of product manufacturing." WuJun said.

        Attaches great importance to the research and development: traditional Chinese medicine research institute was established in Cambridge

        As a national high-tech enterprise, xiangxue pharmacy high-speed development, thanks to the company sustained investment in modern traditional Chinese medicine science and technology innovation, and listed the rapid construction of post-modern Chinese medicine integrated innovation system.

        Companies in 2000 took the lead in domestic compound Chinese medicine fingerprint quality control technology research and development, improve technical level of the related studies, and the scientific research achievements in the industrialization of Chinese herbal medicine production and management.

        Companies to participate in the revised antiviral oral liquid quality standard and feature maps quality testing standards, respectively the China pharmacopoeia (2010 edition) and the China pharmacopoeia (2010 edition) the first supplement publication Guided by the key quality control technology of product modification for the independent intellectual property rights, greatly enhance the product market competition ability.

        Company early in 2007, has been from a strategic layout, in Cambridge, England set up China's pharmaceutical enterprises in Europe the xiangxue Cambridge - the first Chinese medicine research institute of Chinese medicine research center.

        After listed, the company further speed up the construction of modern Chinese medicine integrated innovation system, completed the engineering technology research and development center technical renovation project, further improve and perfect the hardware conditions of scientific research.

        With Yao Xinsheng academicians, jinan university scientific research team in 2011, founded the first batch of enterprises in guangdong province academician workstation, xiangxue in guangdong province traditional Chinese medicine and natural medicine academician workstation; With the Chinese academy of sciences, tianjin university of traditional Chinese medicine the first affiliated hospital of traditional Chinese medicine clinical research unit cooperation, such as adopt internationally recognized clinical research method, carry out multicenter, large sample after TCM products listed clinical evaluation, has been gradually built forms: traditional Chinese medicine (TCM) chemical separation, detection and appraisal technology platform; Advanced quality control technology and manufacturing process technology platform; Efficacy, pharmacology, and toxicology research technology platform; Product before clinical evaluation technology platform platform together with modern Chinese medicine key technologies such as integrated innovation system, the company fully technical support of endogenous growth.

        In addition, the company also through the independent research and development, technical cooperation and talent introduction of a variety of ways, such as investment in research and development of the modern, new dosage form of new drug of TCM, the international leader in the biological medicine and chemical medicine, brain cancer in the next few years of explosive growth for the company ready to reserve talents, technology, products.

        Integrated with modern medicine innovation as the source for modern, capitalization, informationization, internationalization of the management system as the carrier, xiangxue pharmacy strategic integration of Chinese medicine industry has pulled open the curtain. With endogenous type, extension type and the three-dimensional growth model of explosive, xiangxue pharmacy as modern Chinese medicine LingJunXing enterprise takeoff just around the corner.

        Since listed on the gem, the guangzhou xiangxue pharmacy co., LTD. (hereinafter referred to as the "xiangxue pharmacy") in modern Chinese medicine integrated innovation system as the core, with the help of funds of listed after the advantage, has initially completed the strategic layout of Chinese traditional medicine industry integration. In the first quarter of 2013, according to the financial report of the company's main business has maintained a good momentum of development. January to march, the company business income is 208.5442 million yuan, up 50.25%; Profit of 24.891 million yuan, up 37.09%, attributable to the parent company shareholders net income of 21.2643 million yuan, up 43.05% from a year earlier. Xiangxue pharmacy drug firms merger and acquisition of Chinese medicine science and technology innovation, acquisitions of forward-looking, are constantly to create better returns for investors.

        Article source: China JingJiWang